GreenLight Biosciences, Inc.
200 Boston Avenue
About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible.
GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.
GreenLight is currently innovating in both the agriculture and life sciences industries. We aim to bring safe, effective solutions to market that are driven by rigorous scientific innovation. With your skills, you can help us get there.
CEO Andrey Zarur on the personal reason he founded GreenLight Biosciences
53 articles about GreenLight Biosciences, Inc.
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
GreenLight Biosciences, Inc. , an integrated life sciences company developing RNA-based products for plant health, human health and animal health, today announced Charu Manocha as the company's new Chief People Officer.
GreenLight Biosciences Receives $3.3 Million Grant to Develop Sickle Cell Disease Cure Using mRNA Gene Therapy
GreenLight Biosciences has received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges. The funding will support GreenLight's research and testing of affordable therapies using the company's novel messenger RNA (m
GreenLight Biosciences supercharges its efforts with $102M Series D funding from top-tier investors including Morningside Ventures, S2G Ventures and Lupa Systems
GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricult
GreenLight Biosciences closed an oversubscribed $17 million “special purpose funding round” in order to expand its scalable mRNA manufacturing capability for its mRNA COVID-19 vaccine. The goal is to be able to produce billions of doses.
GreenLight Biosciences raises $17M financing round to accelerate large-scale manufacturing of future COVID-19 vaccines
GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine
As part of its expansion into human health, GreenLight Biosciences, Inc. is pleased to welcome the first members of its new Life Sciences Advisory Board.
Represents the Highest Recognition Awarded by the Mexican Senate
He has over 20 years of global agriculture sales, marketing, business development and business leadership experience with Syngenta and DuPont.
Unique Cell-Free Bioproduction Platform delivers cost effective, high quality RNA solutions to human, animal and crop challenges
Mick Messman Brings Over 20 Years of Global Agricultural Sales, Marketing, Product Development and Operations Experience to GreenLight